UK Markets open in 2 hrs 56 mins
  • NIKKEI 225

    29,115.49
    +166.76 (+0.58%)
     
  • HANG SENG

    28,842.13
    +103.23 (+0.36%)
     
  • CRUDE OIL

    71.24
    +0.33 (+0.47%)
     
  • GOLD FUTURES

    1,866.80
    -12.80 (-0.68%)
     
  • DOW

    34,479.60
    +13.40 (+0.04%)
     
  • BTC-GBP

    27,588.31
    +2,702.42 (+10.86%)
     
  • CMC Crypto 200

    972.08
    +30.26 (+3.21%)
     
  • Nasdaq

    14,069.42
    +49.12 (+0.35%)
     
  • ^FTAS

    4,068.33
    +24.32 (+0.60%)
     

Orion Animal Health’s Bonqat® (pregabalin) receives positive CVMP opinion

·1-min read

ORION CORPORATION PRESS RELEASE 17 MAY 2021 at 15.00 EEST

Orion Animal Health’s Bonqat® (pregabalin) receives positive CVMP opinion

The Committee for Medical Products for Veterinary Use (CVMP) of the European Medicines Agency (EMA) has recommended Bonqat® (pregabalin) for marketing authorisation in the European Union.

The compound is recommended for alleviation of acute anxiety and fear associated with transportation and veterinary visits in cats. The final decision of the European Commission on the marketing authorisation is expected in the coming months.

Pregabalin is a new active substance for veterinary use and it acts in the central nervous system by reducing the release of various neurotransmitters (glutamate and monoaminergic neurotransmitters), resulting in an anxiolytic effect.

Orion has also submitted a new animal drug application for pregabalin to the U.S. Food and Drug Administration (FDA).


Contact person:
Niclas Lindstedt, Vice President, Orion Animal Health, Orion Corporation
tel. +358 10 426 4116

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
www.orion.fi

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are neurological disorders, oncology and respiratory diseases for which Orion develops inhaled pulmonary medication. Orion's net sales in 2020 amounted to EUR 1,078 million and the company had about 3,300 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.